EGFR and cancer: Epidermal growth factor receptor has been recognized as an effective anti‐cancer target for decades 4, 5, and EGFR‐targeted therapies, including monoclonal antibodies (mAbs) and small‐molecule tyrosine kinase inhibitors (TKIs), have been successfully applied in the clinic, showing promising outcome in selected patients 6, 7, 8, 9.